CSPC Pharmaceutical Group (HKG:1093) said the biologic license application for the ustekinumab injection has been accepted by China's National Medical Products Administration, a Tuesday bourse filing said.

The ustekinumab injection has been developed by CSPC Megalith Biopharmaceutical, a unit of the pharmaceutical company said.

The injection is a therapeutic biological product for the indication of plaque psoriasis in adults and children.